S E Nissen

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Med 118:22-7. 2005
  2. ncbi Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:103S-112S. 2003
  3. ncbi Perspective: effect of rosiglitazone on cardiovascular outcomes
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Cardiol Rep 9:343-4. 2007
  4. ncbi Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:2457-71. 2007
  5. ncbi Effect of torcetrapib on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:1304-16. 2007
  6. ncbi Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 290:2292-300. 2003
  7. ncbi Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 291:1071-80. 2004
  8. ncbi Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 297:1362-73. 2007
  9. ncbi Imaging and peroxisome proliferator-activated receptor agonists: uncovering their role in atherosclerosis development
    Steven E Nissen
    Cleveland Clinic Cardiovascular Coordinating Center C5, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cardiol 27:IV17-20. 2004
  10. ncbi Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arch Intern Med 170:1191-1201. 2010

Detail Information

Publications92

  1. ncbi Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Med 118:22-7. 2005
    ..The differences in the progression rate are likely to be a result of greater reduction in atherogenic lipoproteins and hs-CRP with intensive therapy...
  2. ncbi Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:103S-112S. 2003
    ..Statins and other agents decrease the incidence of death and MI by stabilizing atherosclerotic plaques throughout the coronary bed, reducing inflammation, collagen degradation, tissue factor expression, and vasomotor tone...
  3. ncbi Perspective: effect of rosiglitazone on cardiovascular outcomes
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Cardiol Rep 9:343-4. 2007
  4. ncbi Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:2457-71. 2007
    ..Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined...
  5. ncbi Effect of torcetrapib on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:1304-16. 2007
    ..Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, increases HDL cholesterol levels, but the functional effects associated with this mechanism remain uncertain...
  6. ncbi Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 290:2292-300. 2003
    ..Infusion of recombinant ApoA-I Milano-phospholipid complexes produces rapid regression of atherosclerosis in animal models...
  7. ncbi Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 291:1071-80. 2004
    ..Statin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality. However, the optimal strategy and target level for lipid reduction remain uncertain...
  8. ncbi Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 297:1362-73. 2007
    ..Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported effects of more potent and selective agents...
  9. ncbi Imaging and peroxisome proliferator-activated receptor agonists: uncovering their role in atherosclerosis development
    Steven E Nissen
    Cleveland Clinic Cardiovascular Coordinating Center C5, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cardiol 27:IV17-20. 2004
    ....
  10. ncbi Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arch Intern Med 170:1191-1201. 2010
    ..Controversy regarding the effects of rosiglitazone therapy on myocardial infarction (MI) and cardiovascular (CV) mortality persists 3 years after a meta-analysis initially raised concerns about the use of this drug...
  11. ncbi Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 294:2581-6. 2005
    ....
  12. ncbi Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 292:2217-25. 2004
    ..The effect of antihypertensive drugs on cardiovascular events in patients with coronary artery disease (CAD) and normal blood pressure remains uncertain...
  13. ncbi Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 352:29-38. 2005
    ..Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression...
  14. ncbi Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 295:1556-65. 2006
    ....
  15. ncbi Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 96:61F-68F. 2005
    ..These differences are related to the greater reduction in atherogenic lipoproteins and CRP in intensively treated patients...
  16. ncbi Effect of ACAT inhibition on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:1253-63. 2006
    ..The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects...
  17. ncbi Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 299:1561-73. 2008
    ..Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers...
  18. ncbi Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 299:1547-60. 2008
    ..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
  19. ncbi A much-anticipated FDA reform bill is signed into law: progress and compromise
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Curr Cardiol Rep 10:1-2. 2008
  20. ncbi Intravascular ultrasound: novel pathophysiological insights and current clinical applications
    S E Nissen
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 103:604-16. 2001
    ..Ultrasound has proven useful in evaluating brachytherapy. New and emerging applications for IVUS are continuing to evolve, particularly in atherosclerosis regression-progression trials...
  21. ncbi Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Circulation 112:2043-6. 2005
  22. ncbi ENHANCE and ACCORD: controversy over surrogate end points
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Curr Cardiol Rep 10:159-61. 2008
  23. ncbi Courage under fire: what is the optimal approach to initial treatment of stable angina?
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Curr Cardiol Rep 10:79-80. 2008
  24. ncbi Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis
    Steven E Nissen
    Cleveland Clinic Foundation, Department of Cardiology, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:24B-31B. 2002
    ..IVUS is likely to emerge as the "gold standard" in the study of atherosclerosis progression-regression over the next few years...
  25. ncbi Atherosclerosis in 2010: new therapeutic insights
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Nat Rev Cardiol 8:70-2. 2011
    ..Key studies in 2010 contributed to the resolution of these long-standing controversies...
  26. ncbi Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study
    F Van Lente
    Department of Clinical Pathology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 33:471-8. 1999
    ....
  27. ncbi Prediction of short- and long-term outcomes by troponin T levels in low-risk patients evaluated for acute coronary syndromes
    I V Peacock WF
    Departments of Emergency Medicine, Cardiology, Clinical Pathology, and Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, OH 44195, USA
    Ann Emerg Med 35:213-20. 2000
    ..However, there are few studies validating this strategy. The purpose of this study was to determine the ability of cTnT levels to predict short- and long-term outcomes in low-risk patients with suspected acute coronary syndromes...
  28. ncbi Comparison of troponin T versus creatine kinase-MB in suspected acute coronary syndromes
    E S McErlean
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 85:421-6. 2000
    ..A negative cardiac marker value (TnT or CK-MB) does not necessarily confer a low risk of complication in patients presenting with acute chest pain to an emergency department...
  29. ncbi Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1553-7. 2006
    ..These results highlight the need for aggressive risk factor modification and a decrease in vascular inflammation in obese patients...
  30. ncbi Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:67-74. 2006
    ..In this study, IVUS will be used to assess whether ACAT inhibition modifies progression of atherosclerotic plaque...
  31. ncbi High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound
    E M Tuzcu
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 103:2705-10. 2001
    ..Detailed, in vivo data on atherosclerosis in young individuals are limited. Intravascular ultrasonography provides a unique opportunity for in vivo characterization of early atherosclerosis in a clinically relevant context...
  32. ncbi Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study
    J Jimenez
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Heart Lung Transplant 20:393-8. 2001
    ..However, de novo lesions continue to develop every year. In patients with evidence of rejection, the rate of progression of transplant vasculopathy correlates with the severity of rejection...
  33. ncbi Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 47:1967-75. 2006
    ..Many risk factors did not predict angiographic disease severity, suggesting different mechanisms drive stenosis development and atheroma accumulation...
  34. ncbi Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study
    Seung Hyuk Choi
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Am Coll Cardiol 52:24-32. 2008
    ..This study was designed to test the hypothesis that circulating biomarkers of oxidized low-density lipoprotein (OxLDL) are affected by statin therapy and predict changes in atheroma volume...
  35. ncbi Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study
    S R Kapadia
    Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 38:206-13. 2001
    ..Therefore, maintenance of LDL cholesterol as close to pretransplant values as possible may help to limit the rate of progression of acquired allograft vasculopathy...
  36. ncbi Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial
    Ilke Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Atherosclerosis 189:229-35. 2006
    ..Measurement of changes in lumen size may not be an accurate method to study progression and regression of atherosclerotic lesions with <50% stenosis...
  37. ncbi Do the extent and direction of arterial remodelling predict subsequent progression of coronary atherosclerosis? A serial intravascular ultrasound study
    I Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio, USA
    Heart 94:623-7. 2008
    ..The objective of this study was to examine whether extent and direction of arterial remodelling are predictors of progression of coronary atherosclerosis. Design, setting and..
  38. ncbi Prognostic value of absolute versus relative measures of the procedural result after successful coronary stenting: importance of vessel size in predicting long-term freedom from target vessel revascularization
    K M Ziada
    Department of Cardiology, Cleveland Clinic Foundation, OH, USA
    Am Heart J 141:823-31. 2001
    ..This emphasizes the role of the vessel size as the limiting factor in determining the long-term outcome of coronary stenting...
  39. ncbi Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study)
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 96:1636-9. 2005
    ..These results suggest that intensive lipid lowering can have a dramatic effect on atheroma-prone regions and that remodeling in response to changes in plaque is a heterogenous process...
  40. ncbi The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, OH 44195, USA
    Arch Intern Med 170:478-84. 2010
    ..We sought to investigate the association of MetS and its component risk factors with progression of coronary atherosclerosis...
  41. ncbi Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JACC Cardiovasc Interv 2:672-8. 2009
    ..We investigated attenuated plaque (hypoechoic plaque with deep ultrasonic attenuation despite absence of bright calcium) in nonculprit lesions...
  42. ncbi Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis
    P Schoenhagen
    Cleveland Clinic Foundation, Ohio 44195, USA
    J Am Coll Cardiol 38:297-306. 2001
    ..In this review, we will analyze the role of remodeling in the progression and regression of native CAD, as well as its impact on restenosis after coronary intervention...
  43. ncbi Using troponin T to diagnose acute coronary syndromes
    E McErlean
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 67:843-9. 2000
    ..Often, measuring both markers provides additional information. This article provides a diagnostic algorithm for using both markers...
  44. ncbi Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis
    Ilke Sipahi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 48:833-8. 2006
    ..e., systolic BP <120 mm Hg and diastolic BP <80 mm Hg). This study suggests that in patients with coronary artery disease, the optimal BP goal may be substantially lower than the <140/90 mm Hg level...
  45. ncbi Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano
    Stephen J Nicholls
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 47:992-7. 2006
    ..After infusion of rHDL containing AIM, regression of coronary atherosclerosis is accompanied by reverse remodeling of the EEM, resulting in no change in luminal dimensions...
  46. ncbi Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound
    Paul Schoenhagen
    Department of Radiology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Coron Artery Dis 14:459-62. 2003
    ..90 (reader 1) and 0.87 (reader 2). CONCLUSION: State-of-the-art MSCT can accurately identify mildly stenotic coronary atherosclerosis and provide an assessment of morphology and remodeling response...
  47. ncbi Assessing coronary plaque burden and plaque vulnerability: atherosclerosis imaging with IVUS and emerging noninvasive modalities
    Paul Schoenhagen
    Department of Cardiovascular Medicine and Radiology, Section of Cardiovascular Imaging, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart Hosp J 1:164-9. 2003
    ..Intravascular ultrasound is the most established invasive method with a long clinical track record. More recently, noninvasive modalities including computed tomography and magnetic resonance imaging are emerging...
  48. ncbi Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation
    Paul Schoenhagen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arterioscler Thromb Vasc Biol 23:1895-900. 2003
    ....
  49. ncbi Prognostic value of myeloperoxidase in patients with chest pain
    Marie-Luise Brennan
    Department of Cell Biology, Cleveland Clinic Foundation, Cleveland 44195, USA
    N Engl J Med 349:1595-604. 2003
    ....
  50. ncbi Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration
    Paul Schoenhagen
    Department of Cardiology and Biomedical Engineering, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Am Soc Echocardiogr 16:277-84. 2003
    ..99). CONCLUSIONS: Area measurements vary among different intravascular ultrasound catheter systems. Calibration equations can correct for these differences and allow the comparison of measurements among catheters...
  51. ncbi Risk of cardiovascular events associated with selective COX-2 inhibitors
    D Mukherjee
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F 25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 286:954-9. 2001
    ..The available data raise a cautionary flag about the risk of cardiovascular events with COX-2 inhibitors. Further prospective trial evaluation may characterize and determine the magnitude of the risk...
  52. ncbi Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 9:266-73. 2007
    ..The current state of evidence defining the relative contribution of changes in plasma lipids on the tendency to plaque regression is reviewed...
  53. ncbi Relationship between residual atheroma burden and neointimal growth in patients undergoing stenting: analysis of the atherectomy before MULTI-LINK improves lumen gain and clinical outcomes trial intravascular ultrasound substudy
    Ivan P Casserly
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Coll Cardiol 40:1573-8. 2002
    ..1, p = 0.62). CONCLUSIONS: This study failed to demonstrate a clinically significant relationship between quantitative volumetric and cross-sectional measures of residual atheroma burden and subsequent neointimal growth...
  54. ncbi Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade
    Nezihi Baris
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Heart Lung Transplant 26:593-7. 2007
    ....
  55. ncbi New targets of high-density lipoprotein therapy
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Lipidol 18:421-6. 2007
    ..Currently available therapies raise levels of HDL-cholesterol by relatively modest amounts. This review describes experimental strategies that promote HDL activity...
  56. ncbi Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 55:2399-407. 2010
    ..The aim of this study was to investigate the relationship between intravascular ultrasound (IVUS)-derived measures of atherosclerosis and cardiovascular outcomes...
  57. ncbi Cardiogenic shock in the setting of severe aortic stenosis: role of intra-aortic balloon pump support
    Olcay Aksoy
    Department of Cardiovascu Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Heart 97:838-43. 2011
    ..To investigate the haemodynamic effects of intra-aortic balloon pump (IABP) support in patients with severe aortic stenosis (AS) presenting in cardiogenic shock (CS)...
  58. ncbi Influence of coronary pulsation on volumetric intravascular ultrasound measurements performed without ECG-gating. Validation in vessel segments with minimal disease
    Hiroshi Tsutsui
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Cardiovasc Imaging 19:51-7. 2003
    ..Despite these limitations, this method is feasible and provides reproducible volume measurements...
  59. ncbi Coronary atherosclerosis in diabetic subjects: clinical significance, anatomic characteristics, and identification with in vivo imaging
    Paul Schoenhagen
    The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cardiol Clin 22:527-40, vi. 2004
    ....
  60. ncbi ETC-216 for coronary artery disease
    Stephen J Nicholls
    Heart and Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, OH 44195, USA
    Expert Opin Biol Ther 11:387-94. 2011
    ....
  61. ncbi Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction
    Stephen J Nicholls
    Department of Cardiovascular Medicine and Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, 9500 Euclid Ave, NE 10, Cleveland, OH 44195, USA
    Circulation 116:2315-24. 2007
    ..It is unclear whether abnormalities of arginine and nitric oxide metabolism are related to hemodynamic dysfunction and mortality in patients with cardiogenic shock (CS) after acute myocardial infarction...
  62. ncbi Rate of progression of coronary atherosclerotic plaque in women
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1546-51. 2007
    ....
  63. ncbi Noninvasive imaging of coronary arteries: current and future role of multi-detector row CT
    Paul Schoenhagen
    Department of Radiology, Cleveland Clinic Foundation, Desk Hb 6, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Radiology 232:7-17. 2004
    ..It will describe how tomographic coronary imaging may eventually supplement traditional angiographic techniques in understanding the patterns of atherosclerotic CAD development...
  64. ncbi Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 55:2736-42. 2010
    ..The purpose of this study was to characterize the determinants of plaque progression despite achieving very low levels of low-density lipoprotein cholesterol (LDL-C)...
  65. ncbi Intravascular ultrasonography: using imaging end points in coronary atherosclerosis trials
    Paul Schoenhagen
    Department of Radiology, Section of Cardiovascular Imaging, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 72:487-9, 493-6. 2005
    ..Other imaging tests may also prove useful to monitor treatment of atherosclerosis and identify populations at risk for coronary artery disease (CAD)...
  66. ncbi Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial
    Paul Schoenhagen
    FAHA, Department of Cardiovascular Medicine, Cardiovascular Imaging, The Cleveland Clinic Foundation, HB 6, 9500 Euclid Ave, Cleveland OH 44195, USA
    Circulation 113:2826-34. 2006
    ..However, the remodeling response during plaque-stabilizing therapy and its relationship to markers of lipid metabolism and inflammation are incompletely understood...
  67. ncbi Identification of the metabolic syndrome and imaging of subclinical coronary artery disease: early markers of cardiovascular risk
    Paul Schoenhagen
    Department of Cardiovascular Medicine, Cardiovascular Imaging, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Cardiovasc Nurs 21:291-7. 2006
    ....
  68. ncbi Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation
    E Murat Tuzcu
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:1538-42. 2005
    ..The aim of this study was to determine whether angiographically silent early coronary intimal thickening could predict long-term morbidity and mortality...
  69. ncbi Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Circulation 118:2506-14. 2008
    ..We investigated the relationship between lipid changes and progression of coronary atherosclerosis...
  70. ncbi Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial
    Ilke Sipahi
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:544-50. 2006
    ..This is due to concomitant remodeling of the reference sites used in the static assessment. Intravascular ultrasound performed at a single point in time does not reflect the dynamic remodeling response...
  71. ncbi Coronary atherosclerosis can regress with very intensive statin therapy
    Ilke Sipahi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:937-44. 2006
    ....
  72. ncbi Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular So
    Sorin J Brener
    Department of Cardiovascular Medicine and Biostatistics, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:1059-63. 2006
    ..We set out to explore the relationship between quantitative coronary angiography parameters, baseline characteristics, and clinical events in a large trial of CAD regression with antihypertensive agents...
  73. ncbi Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials
    Andrea J Lavoie
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:1679-83. 2010
    ..These minimally diseased arteries demonstrated evidence of vessel and luminal constriction, regardless of the angiographic appearance...
  74. ncbi Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 99:813-6. 2007
    ..In conclusion, findings suggest that the increased incidence of clinical events in patients with impaired renal function may result from factors other than atherosclerotic burden...
  75. ncbi Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 57:1111-9. 2011
    ..The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent designed to enhance apolipoprotein (apo) A-I synthesis...
  76. ncbi Intravascular ultrasound in cardiovascular medicine
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ65, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
    Circulation 114:e55-9. 2006
  77. ncbi Coronary atherosclerotic disease burden: an emerging endpoint in progression/regression studies using intravascular ultrasound
    Paul Schoenhagen
    The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Curr Drug Targets Cardiovasc Haematol Disord 3:218-26. 2003
    ..This review will summarize the rational of this approach and describe the use of intravascular ultrasound (IVUS) for such studies...
  78. ncbi Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome
    Ozgur Bayturan
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 105:1735-9. 2010
    ..This finding highlights the deleterious effects of DM on the arterial wall independent of its associated metabolic abnormalities...
  79. ncbi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JAMA 297:499-508. 2007
    ..However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression...
  80. ncbi Coronary artery calcification and changes in atheroma burden in response to established medical therapies
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:263-70. 2007
    ..This study sought to determine the relationship between coronary calcification and plaque progression in response to established medical therapies...
  81. ncbi Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:255-62. 2008
    ..Our goal was to characterize coronary atherosclerosis progression and arterial remodeling in diabetic patients...
  82. ncbi Pharmacologic strategies for the prevention of atherosclerotic plaque progression
    Paul Schoenhagen
    The Cleveland Clinic Foundation, Department of Radiology, Cardiovascular Imaging, Radiology Desk Hb 6, Cleveland, OH 44195, USA
    Expert Rev Cardiovasc Ther 2:855-66. 2004
    ..This review will describe the use of intravascular ultrasound for such studies, summarize results from recent trials and outline potential future pharmacologic targets...
  83. ncbi Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Mail Code JJ 65, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 12:301-7. 2010
    ..The relationship between high-density lipoprotein and progression of atherosclerosis and its implications for clinical practice are reviewed here...
  84. ncbi Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JAMA 298:1180-8. 2007
    ..Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence is mixed regarding the influence of medications of this class on cardiovascular outcomes...
  85. ncbi Surrogate markers for atherosclerotic disease
    Raaj R Sankatsing
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Curr Opin Lipidol 16:434-41. 2005
    ..Awaiting further technical improvements, CMR is expected to provide the most valuable information for the evaluation of atherosclerosis in the near future...
  86. ncbi Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex 77030, USA
    Circulation 117:2458-66. 2008
    ..Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing...
  87. ncbi Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance
    Umesh N Khot
    Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland Heights, OH 44195, USA
    J Am Coll Cardiol 40:218-9. 2002
    ..Furthermore, clopidogrel increased bleeding risk in early cardiac surgery. Thus, widespread usage of clopidogrel, especially in centers with an early revascularization strategy, will have limited clinical benefit with considerable risk...
  88. ncbi Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study
    H Tsutsui
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:653-7. 2001
    ..Changes in the EEM area showed a biphasic response, consisting of early expansion and late constriction. Thus, different mechanisms of lumen loss were observed during the early and late phases after transplantation...
  89. ncbi Normal CK, elevated MB predicts complications in acute coronary syndromes
    W F Peacock
    Department of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Emerg Med 20:385-90. 2001
    ..These patients should be considered as having had an acute coronary syndrome...
  90. ncbi Quantitative detection of outlet strut separations in Björk-Shiley convexo-concave mitral valves
    K A Powell
    Department of Biomedical Engineering, Cleveland Clinic Foundation, OH 44195, USA
    Circulation 94:3251-6. 1996
    ..The goal of the present study was to develop an objective postprocessing technique to evaluate outlet strut leg integrity quantitatively in these cineradiographic images...
  91. ncbi [Imaging of coronary atherosclerotic plaque]
    P Schoenhagen
    The Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F-25, 9500 Euclid Ave, Cleveland OH 44195, USA
    Z Kardiol 92:429-37. 2003
    ..Current developments in particular of computed tomography already allow the non-invasive imaging of coronary arteries and may have an important role in the early identification of CAD and the prevention of its complications...
  92. ncbi Left main trunk coronary artery dissection as a consequence of inaccurate coronary computed tomographic angiography
    Matthew C Becker
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arch Intern Med 171:698-701. 2011
    ....